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Summary: A solid phase, enzyme-linkcd immunoassay is described for the quantitative determination of the
complex of human granulocyte elastase (EC 3.4.21.37) with αι-proteinase inhibitor. The assay employs anti-
body-coated test tubes and it is suitable for routine use in clinical chemistry laboratories. Data for sample
stability and test characteristics are given. A reference r nge of 20—180 μg/l elastase in plasma was deter-
mined. The diagnostic significance of granulocyte elastase levels in plasma in inflammatory diseases is dis-
cussed.
„PMN-Elastase Assay": Enzymimmunassay zur Bestimmung des Komplexes von menschlicher Granulocyten-
Elastase mit a/-Proteinaseinhibitor
Zusammenfassung: Es wird ein Festphasen-Enzymimmunoassay zur quantitativen Bestimmung des Kom-
plexes aus menschlicher Granulocyten-Elastase und arProteinaseinhibitor beschrieben. Es handelt sich um
eine routinef hige Testversion mit Antik rper-beschichteten R hrchen. Daten zur Stabilit t von Proben und
die Testcharakteristica werden angegeben. Als Referenzbereich f r Elastase im Plasma wurden 20—180 μο/1
ermittelt. Die Bedeutung der Granulocyten-Elastase im Plasma f r die Diagnose und Verlaufskontrolle von
entz ndlichen Prozessen wird diskutiert.
Introduction
Human polymorphonuclear neutrophilic leukocytes
contain large amounts of neutral proteinases which
are released when the granulocyte? are exposed to a
phagocytic Stimulus. In inflammatory diseases local
imbalance between these proteinases and available
proteinase inhibitors may cause tissue injury s well
s degradation of plasma proteins (1). Granulocyte
elastase (EC 3.4.21.37) is of special pathological in-
terest because of its high concentration and its broad
specificity for a variety of connective tissue compo-
nents (i.e. elastin, collagen, proteoglycans) and plas-
ma proteins (i.e. IgG, complement factors €3 and'
C5, various clotting factors), cf. I.e. (2, 3). Clearly,
the quantitative determination of elastase in in-
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flamed tissue and in the circulating blood should
provide Information on connective tissue diseases,
but only a few reports have so far been published on
quantitative assays for the detection and quantita-
tion of elastase in biological fluids (4—7, 18). The
main inactivating agent in plasma for elastase is αι-
proteinase inhibitor (8). Elastase intcracts with the
inhibitor to form a complex with a molar ratio of l to
l and a molecular weight of approximatcly 80.000
Daltons (8).
We developed a solid phase enzyme-linked immu-
noassay for the determination of the complex of
elastase with αι-proteinase inhibitor (9, 10). In this
paper we describe a rapid assay version in test tubes
for routine use in the clinical chemistry laboratory.
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Materials and Methods
Reagents
All rcagents were from E. Merck, unless stated otherwise.
Sepharose 6 B® and Concanavalin A-Sepharose® were from
Deutsche Pharmacia; CM-Cellulose CM 52 was from Whatman
Biochemicals Ltd; Methoxysuccinyl-L-ala-L-ala-L-pro-L-val-4-
nitroanilide was from Bachern AG.
G r a n u l o c y t e e las tase and an t i bod i e s
Elastase was isolated from granule extracls of normal human gra-
nulocytes by a procedure described previously (11). The prepara-
tion was free of contaminant granul r or serum proteins s shown
by polyacrylamide gel electrophoresis at pH 4.5, and by immu-
noelectrophoresis with antisera against granul r extract and hu-
man serum.
Antisera against elastase were raised in sheep and were shown to
be antigen-specific by immunoelectrophoresis. The immunoglo-
bulin G fraction was isolated with the use of caprylic acid and ion-
exchange fractionation.
a i - P r o t e i n a s e > i n h i b i t o r and ant ibodies
Human arproteinase inhibitor was isolated from outdated plas-
ma. The purification procedure consisted of affinity chromatogra-
phy on Fractogel® TSK-Red, ion exchange chromatography on
Fractogel® TSK DEAE-650, and gel filtration on Fractogel® TSK
HW-55 according to I.e. (12). The resulting preparation of ar
proteinase inhibitor was further purified by chromatography on
Concanavalin A-Sepharose® (2.6 cm x 20 cm), previously equili-
brated with 50 mmol/1 Tris/HCl buffer pH 7.5 containing l
mmol/1 MgCh, l mmol MnCb, and l mmol/1 CaCb. Unbound
material was washed from the column with the same buffer. ar
Proteinase inhibitor was eiuted by adding 0.1 mol/1 methyl a-D-
mannoside to the buffer. The final protein preparation was homo-
geneous s judged by a polyacrylamide gel electrophoresis at
pH 9.0, and by immunoelectrophoresis. Antisera against oti-pro-
teinase inhibitor were raised in rabbits and were shown to be anti-
gen-specific by immunoelectrophoresis against human serum.
Coating
Polystyrene tubes 10.5 x 40 mm (Greiner No. 655061) were co-
ated by incubation with a solution containing 50 mg/1 antibodies
against elastase in 10 mmol/1 ammonium hydrogen carbonate,
pH 7.8, overnight at 4°C.
Prepara t ion of label led an t ibodies
Antibodies against arproteinase inhibitor were purified from
rabbit antiserum, coupled to calf intestinal alkaline phosphatase
by a one step glutaraldehyde procedure, and the labelled antibo-
dies were isolated by gel filtration s described in a separate paper
(13). .·,
Complex f o r m a t i o n
The elastase/cti-proteinase inhibitor complex was produced by
mixing elastase with an excess of the inhibitor. Elastase (0.5 mg)
and αι-proteinase inhibitor (2.8 mg) were incubated fof 30 min at
37 °C in 2 ml 30 mmol/1 tris(hydroxymethyl)aminomethane/HCl
buffer pH 8.0, containing 85 mmol/1 NaCl. Under these condl·
tions elastase is totally inactivated by complex formation s shown
by assay of the catalytic ctivity using methoxysuccinyl-L-aia-L-
ala-L-pro-L-val-4-nitroanilide (14), immunoelectrophoresis and
polyacrylamide gel electrophoresis at pH 4.3.
The immunoassay
The assay principle is given in figure 1.
Step l Dilute one volume of plasma with 50 Volumes of phos-
phate-buffered saline containing 10 g/l bovine serum al-
bumin and 20 mmol/1 EDTA.
Step 2 Incubate 500 μΐ sample diluent, Standard or diluted sam-
ple per tube l h at room temperature.
Step 3 Wash three times with distilled water containing 0.5 g/l
polyoxyethylene sorbitan monolaurate.
Step 4 Incubate with 500 μΐ reagent containing alkaline phospha-
tase labelled rabbit-IgG against arproteinase inhibitor
l h at room temperature.
Step 5 Wash once with distilled water containing 0.5 g/l poly-
oxyethylene sorbitan monolaiirate.
Step 6 Incubate with 500 μΐ 10 mmol/1 4-nitfophenyl phosphate
in l mol/1 diethanolamine/HCl-buffer pH 9.8 containing
0.5 mmol/1 MgCJ2.
Step 7 Stop enzyme reaction by adding 500 μΐ 2 mol/1 NaOH.
Step 8 Read absorbance at 405 nm.
Solid phase
antibody to
elastase
4- Sample Complex of +
elastase with
inhibitor fixed to
solid phase
antibody
Antibody to
inhibitor
labelled with
alkaline
phosphatase
Complex formed by solid
phase antibody, enzyme-
inhibitor-complex and
labelled antibody to
inhibitor
4-Nitrophenolate
A40S nm
4-Nitrophenylphosphate
Fig. 1. Principle of solid-phase, enzyme-linked immunoassay for polymorphonuclear elastase complexed with arproteinase inhibitor
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Standard Solut ions and control plasma
Standard Solutions with defined levels of complexed elastase were
prepared by diluting the reaction mixture with phosphate-buf-
fered saline containing 10 g/l bovine serum albumin. Control plas-
ma with a known level of the complex was produced s follows:
Citrated plasma from non-immunized sheep was inactivated at
56 °C for 45 min and mixed with a defined amount of elastase-ar
proteinase inhibitor complex.
Detection l imi t
The lower limit of sensitivity, s defined by the mean
absorbance of the blanks plus three Standard devia-
tions, was 0.25 ng per test tube. The detection limit
was increased by increasing the reaction periods in
Step 2 and Step 4 of the assay (see section "The im-
munoassay").
Sample col lect ion
Citrated or EDTA plasma was used. Plasma was separated from
blood within 30 min after sample collection to prevent interfer-
ence by in vitro secretion by leukocytes (15, 16). Tests were per-
formed either on fresh plasma or on aliquots stored frozen at
-20 °C or -70 °C.
Precision
Precision was monitored with different plasma pools
(tab. 1). Within-run imprecision (coefficient of Vari-
ation) was 4 to 8%, and between-run imprecision
was in the r nge of 3 to 8% CV.
Results
Standard curve
The absorbance values obtained with sample diluent
and the Standard Solutions were plotted versus con-
centration on a linear diagram (fig. 2). The intercept
at 0 μg/l and the slope were calculated by linear re-
gression. Absorbance readings from unknown sam-
ples were referred to the calibration curve.
The working r nge of the assay is 0.5 to 5.0 ng of
elastase in complex with αι-proteinase inhibitor in
the assay tube. This is equal to a r nge of 51 to 510
μg/l in plasma when testing plasma samples diluted l
-f 50 in 500 μΐ final volume.
Tab. 1. Precision of the assay.
Sample Elastase Sample Series Exper- CV
volume iments
(|ig/I) (μΐ) series (%)
Within-series imprecision
Pooled plasma 1
Pooled plasma 2
Pathological plasma
52
206
389
20
20
10
1
1
1
15
15
15
7.7
3.9
4.0
Between-series imprecision
Pooled plasma 1
Pooled plasma 2
Pathological plasma
47
191
339
20
20
10
15
15
15
2
2
2
8.2
7.4
2.9
Elastase I/xg/ll
Fig. 2. Calibration curve for the elastase assay. Absorbance s a
function of concentration (given s μg/l of elastase in the
complex with αι-proteinase inhibitor).
Sample s tab i l i ty
Citrated plasma was stored at least 6 months at
-20°C or 14 days at +2°C to +8°C without ap-
preciable loss of the antigenic reactivity of the elas-
tase/arproteinase inhibitor complex.
Linearity and paral le l i ty
Citrated plasmas were pooled to give a plasma speci-
men with levels of 60 or 500 μg/l of complexed elas-
tase. Linear results were obtained with plasma sam-
ples of 10 to 80 μΐ from the first pool, and with plas-
ma samples of l to 8 μΐ from the second pool. The
slopes of the plasma dilution curves were not signifi-
cantly different from that of the calibration curve
(fig. 3).
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Fig. 3. Linearity and parallelily of the assay. Absorbance s a
function of varying quantities of Standard material or plas-
ma.
Definition of sample volume:
©. Calibrator with 10 ug/1, l = 500 μΐ
D, Pooled human plasma with 60 ug/1, l = 100 μΐ plasma
x, Pooled human plasma with 500 ug/K 1 = 10 μΐ plasma
Final volume in the test tube was adjusted to 500 μΐ by
addition of sample diluent if necessary. From I.e. (22).
Recovery
Aliquots of the elastase/ai-proteinase inhibitor com-
plex s produced in vitro were added to six different
citrated human plasma samples. The concentrations
of the complex in the native and the spiked plasma
samples were assayed. Recovery was 75 to 96 per-
cent.
P lasma r e f e r ence r nge
The plasma concentration of the elastase/cxj-protein-
ase inhibitor complex was measured in citrated plas-
ma from 172 randomly selected, apparently healthy
laboratory workers. The group consisted of 165
males and 7 females, age r nge 18 to 62 years. The
concentration of complexed elastase was in the r nge
20 to 180 μ£/1 with a mean ± Standard deviation of
67 ± 31 μg/l and a median of 64
Discussion
In recent years evidence has accumulated for the
role of granulocyte elastase s a main pathogenetical
factor in inflammatory processes. However, only a
few reports have appeared on the development of
quantitative laboratory assays for the deterrnination
of granulocyte elastase levels in plasma or other bio-
logical fluids. The immunoassays for granulocytic
elastase reported so far are electroimmunodiffusion
(4), radioimmunoassay (5, 7) and a competitive en-
zyme-linked immunoassay for canine granulocytic
elastase (6). These determination techniques for
elastase have riot found wide application in the clini-
cal chemistry laboratory.
In previous reports it was shown that granulocyte
elastase in plasma is complexed mainly with ai-pro-
teinase inhibitor (8, 17). Elastase in this complex is
devoid of enzymatic activity. A small fraction of the
enzyme is also bound to oto-macroglobulin (8). Gra-
nulocyte elastase in this complex retains some enzy-
matic activity towards a peptide Substrate (14). De-
termination of this activity in plasma does not appear
to be a sensitive parameter for granulocyte elastase,
because the elastase/o^macroglobulin complex rep-
resents only a small fraction of the elastase mole-
cules present in plasma and is elirninated very quick-
ly from the circulation (17). We chose an alternative
approach, i.e. the irnmunochemical quantitation of
the plasma concentration of the complex of elastase
with αι-proteinase inhibitor. This technique rnakes
use of the dual immunological specificity of the
equimolar complex of an enzyme firmly bound to its
inhibitor. In a first assay version microculture plates
were used s carriers for the antibodies against elas-
tase (9, 10). A similar assay which is based on the
same principle was recently,,reported by another
group (18). However, in our view, it is more conve-
nient to use volumes of 0.5 or 1.0 ml for absorption
readings on routine photometers. We therefore
developed a version of the assay^ which employs
polystyrene tubes, and the characteristics of this as-
say are reported here. Both detection limits, within-
series and between-series imprecision, linearity, par-
allelity of calibrators and plasma dilutions and recov-
ery are within reasonable limits. Our method is sen-
sitive, precise and practicable with the equipment of
a routine clinical chemistry laboratory.
A normal r nge of 20 to 180 μg/l was found in a
group of healthy laboratory workers. Work in .pro-
gress will define the reference r nge on different and
enlarged normal groups.
In preliminary clinical studies largely increased plas-
ma levels were found in patients with septicaemia,
polytrauma and in most patients with acute rheuma-
toid arthritis (3, 19, 20, 21). These data suggest a
diagnostic relevance of granulocyte elastase levels in
plasma.
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